Floatz logo

Azacitidine

Breast Cancer Invasive

University of Illinois at ChicagoSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

58 Active assets in the Breast Cancer Invasive cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
University of California, San Francisco
Phase 4BBB
Letrozole
Emory University
Phase 4BBB
Arimidex
Jonsson Comprehensive Cancer Center
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
FULVESTRANT
Massachusetts General Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →